Novartis And GlaxoSmithKline In Multi-Billion Dollar Deals

HFA Padded
Published on
Updated on

Novartis AG (NYSE:NVS) (VTX:NOVN) will acquire GlaxoSmithKline plc (ADR) (NYSE:GSK) (LON:GSK)’s oncology unit for around $14.5 billion, while Glaxo will pay $5.25 billion for Novartis’ vaccines business. The deal comes on the heels of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) revealing plans to acquire the wrinkle treatment maker Allergan Inc. Deal to enhance firms’ core focus While unveiling its fourth quarter earnings in February, GlaxoSmithKline plc (ADR) (NYSE:GSK) (LON:GSK) said its Respiratory, Vaccines and HIV divisions were strengthened by new product launches. It disclosed expanding its respiratory portfolio even further with two major approvals, while reporting over 1,700 prescriptions for its HIV drug…

This content is exclusively for paying members of Hedge Fund Alpha

Log In

Insider Strategies and Letters to Shareholders from the Top Hedge Funds and Maximize Your Portfolio Growth with Hedge Fund Alpha

Don’t have an account?

Subscribe now and get 7 days free!

HFA Padded

Mani is a Senior Financial Consultant. He has worked in Senior Management role in large banking, financial and information technology organizations. He has provided solutions for major banking and securities firms across the globe in the area of retail, corporate and investment banking. He holds MBA (Finance) and Professional Management Accounting Qualifications. His hobbies are tracking global financial developments and watching sports